Conduction System Pacing for Cardiac Resynchronisation

Parkishit S Sharma and Pugazhendhi Vijayaraman

1. Rush University Medical Center, Chicago, IL, US. 2. Geisinger Heart Institute, Wilkes-Barre, PA, US

Abstract

Conduction system pacing (CSP) is a technique of pacing that involves implantation of permanent pacing leads along different sites of the cardiac conduction system and includes His bundle pacing and left bundle branch pacing. There is an emerging role for CSP to achieve cardiac resynchronisation in patients with heart failure with reduced ejection fraction and inter-ventricular dyssynchrony. In this article, the authors review these strategies for resynchronisation and the available data on the use of CSP in overcoming dyssynchrony.

Keywords

Biventricular pacing, cardiac resynchronisation therapy, conduction system pacing, heart failure, His bundle pacing, left bundle branch block, left bundle branch pacing, right bundle branch block, ventricular dyssynchrony

Conduction system pacing (CSP) is a therapy that involves the placement of permanent pacing leads along different sites of the cardiac conduction system with the intent of overcoming sites of atrioventricular (AV) conduction disease and delay, thereby providing a pacing solution that results in more synchronised biventricular activation. Lead placement for CSP can be targeted either at the bundle of His, known as His bundle pacing (HBP), or at the region of the left bundle branch (LBB), known as LBB pacing (LBBP). HBP was first described by Deshmukh et al. in 2000.

There are a number of observational studies that have demonstrated the clinical benefits of HBP over conventional right ventricular (RV) pacing. LBBP was first described by Huang et al. in 2018 and involves placement of a pacing lead through the inter-ventricular septum closer to the main trunk of the LBB, bypassing areas of AV conduction disease. Over the past decade, these techniques have gained significant popularity and specific tools have been designed to enhance lead delivery.

Cardiac resynchronisation therapy (CRT), which has traditionally been performed using biventricular pacing (BVP), in addition to guideline directed medical therapy, is the cornerstone treatment for patients with cardiomyopathy, heart failure (HF) and ventricular dyssynchrony. Although not a new concept, HBP and LBBP have been successful in overcoming bundle branch block (BBB) and result in ventricular synchrony, particularly in patients with more proximal disease. This has allowed the use of these strategies for CRT, either as a first-line therapy or as a rescue strategy when BVP fails.

In this paper, we provide a comprehensive review of CSP for CRT including a review of the available data on CSP among various indications for CRT.

Traditional Biventricular CRT

BVP is the conventional form of CRT (BVP-CRT). It is as an integral part of therapy for patients with HF with depressed left ventricular ejection fraction (LVEF) and a wide QRS, which implies inter-ventricular dyssynchrony. Several large, randomised studies have demonstrated improved quality of life, increased exercise capacity, reduced HF hospitalisation and decreased all-cause mortality with the use of traditional BVP-CRT. The patients who derive the most benefit from BVP-CRT are those with HF with reduced ejection fraction (HFrEF) and left bundle branch block (LBBB). BVP-CRT may also benefit patients who develop an RV pacing-induced cardiomyopathy (PIM), which is another form of ventricular dyssynchrony, and patients with a low LVEF undergoing implantation of a new or replacement pacemaker or ICD with an anticipated requirement for a significant percentage (>40%) of ventricular pacing.

However, about 30% of patients receiving BVP-CRT do not derive a detectable clinical or echocardiographic benefit and some worsen after resynchronisation. Anatomical limitations such as lack of suitable venous branches and unavoidable phrenic nerve stimulation at suitable anatomic LV lead positions affect the success of coronary sinus lead implantation. Finally, certain subsets of patients, such as patients with HF-EF and RBBB or patients with a narrow QRS duration (QRSd) and need for ventricular pacing, may not derive a significant benefit and hence may not be ideal for traditional BVP-CRT.

Conduction System Pacing for CRT

Permanent HBP was first described by Deshmukh et al. for maintenance of inter-ventricular synchrony in a small series of patients with AF and cardiomyopathy undergoing AV node (AVN) ablation. Over the past decade, there has been a reinvigoration in the interest in HBP as more
Conduction System Pacing for CRT

Figure 1: Sites for Conduction System Pacing and Cardiac Resynchronisation Therapy

1. His bundle pacing
2. Left bundle branch pacing
3. Left septal pacing
4. LV epicardial pacing

Possible CRT strategies:
1. HBP-CRT = site 1
2. LLBBP-CRT = site 2
3. BVP-CRT = site 4 and RV endocardium
4. HOT-CRT = site 1 and 4
5. LOT-CRT = site 2 and 4

Locations for permanent lead placement along the atrioventricular conduction system and possible cardiac resynchronisation therapy strategies using conduction system pacing. BVP: biventricular pacing; CRT: cardiac resynchronisation therapy; HBP: His bundle pacing; HOT-CRT = His optimised CRT; LLBBP = left bundle branch pacing; LOT-CRT = left bundle branch pacing optimised CRT.

Barba-Pichardo et al. first described their experience with HBP in failed CRT cases in 2013. HBP was attempted in 16 patients with cardiomyopathy and failed BVP-CRT. Temporary pacing at the HB corrected LLBB in 13 patients (81%). Successful permanent HBP for CRT was achieved in 69% of the patients (n=9). Mean QRSD decreased from 166 ± 8 ms to 97 ± 9 ms. New York Heart Association (NYHA) functional class improved from III to II and there was an improvement in LVEF and LV dimensions. This was one of the first series demonstrating the value of HBP for CRT but the study was limited by its observational nature, small number of participants and low success rates.

Lustgarten et al. performed a crossover study comparing HBP versus BVP-CRT in 29 patients, with successful resynchronisation in 21 (72%) cases. All patients received a coronary sinus LV lead and an HBP lead connected to the LV port with a Y adapter and were randomised in single patient-blinded fashion to either HBP or BVP pacing. Among the 12 patients who completed the crossover analysis, patients from both groups demonstrated significant improvements in LVEF, NYHA functional status and 6-minute walk distance. Although this was the first randomised crossover study evaluating the value of HBP for CRT, only 12 of the 29 patients completed the study.

Ajijola et al. evaluated the value of HBP as an alternative approach to CRT in lieu of coronary sinus lead and this was successful in 16 of the 21 patients in the study (76%). There was a significant narrowing of the QRSD from 180 ± 23 ms to 129 ± 13 ms (p<0.0001) with an improvement in NYHA functional class from III to II (p<0.001), while the mean LVEF and LV internal dimension in diastole at a median follow-up of 12 months improved from 27 ± 10% to 41 ± 13% (p<0.001) and from 5.4 ± 0.4 cm to 4.5 ± 0.3 cm (p<0.001), respectively. This study was a small observational single-centre evaluation and only focused on patients with LLBB.

Sharma et al. reported a multi-centre study of HBP for CRT in 106 patients including HBP as a primary or rescue strategy and reported an overall success rate of 90%. BBB was present in 45% of the patients while 39% cases had a paced rhythm. During a mean follow-up of 14 months, both groups demonstrated significant narrowing of QRS from 157 ± 33 ms to 117 ± 18 ms (p=0.0001), increase in LVEF from 30 ± 10% to 43 ± 13% (p=0.0001) and improvement in NYHA class with HBP. His capture and BBB correction thresholds were 1.4 ± 0.9 V and 2.0 ± 1.2 V at 1 ms, respectively. Lead-related complications occurred in seven patients. Although this study was multicentre and included patients with all indications for CRT, the retrospective nature of this study was a limitation.

Upadhyay et al. conducted a multi-centre randomised pilot study evaluating the value of HBP for CRT compared with BVP-CRT in 41 patients with CRT indications. Of the 41 patients in the study, 35 had an underlying LLBB. Although the crossover rate was high, QRSD was significantly shorter in those that received His-CRT compared to those that received BVP-CRT (125 ± 22 ms versus 164 ± 25 ms; p<0.001). The median change in LVEF was higher for His-CRT compared to BVP-CRT, but this difference was not statistically significant (+7.2% [5.0–16.9%] versus +5.9% [1.5–11.3%]; p=0.17). A trend toward higher rates of echocardiographic response (80% versus 57%; p=0.14) was similarly observed. This was the first multicentre randomised pilot study evaluating His-CRT versus BVP-CRT. Some of the conclusions were limited due to the high crossover rates and the inclusion of patients with intraventricular conduction delay (IVCD) QRS patterns that do not always respond to HBP for CRT.

Hu et al. published data on HBP for CRT in 74 patients with non-ischaemic cardiomyopathy and LLBB. Permanent HBP was successful in 75.7% of the patients (n=56). Over a median follow-up of 3 years, LVEF increased from 32.4 ± 8.9% at baseline to 55.9 ± 10.7% (p<0.001) and NYHA class improved from 2.73 ± 0.58 to 1.03 ± 0.18 (p<0.001). LLBB correction threshold remained stable with an acute threshold of 2.13 ± 1.19 V/0.5 ms and 2.29 ± 0.92 V/0.5 ms at 3-year follow-up (p=0.05). The high responder rate in this study was likely due to its highly selective study population of patients with typical LLBB and non-ischaemic cardiomyopathy.
### Table 1: Study Summary for Conduction System Pacing and Cardiac Resynchronisation Therapy

| Study | Design | Indication | n | Success Rate | Follow-up (Months) | ECG/QRSd | Outcomes |
|-------|--------|------------|---|--------------|-------------------|----------|----------|
| **His Bundle Pacing in Left Bundle Branch Block** | | | | | | | |
| Barba-Pinchardo et al. 2013* | Single centre Prospective Observational | HBP in CRT with dilated LV, LBBB, no coronary venous access | 16 | 56% | 31 | LVEF 29–36% LVEDD 6.6 to 6.0 cm LVEDS 5.5 to 5.1 cm | QRSd 166 to 97 ms | Improved NYHA III to II |
| Lustgarten et al. 2015* | Multicentre Prospective Crossover of HBP versus BV | HBP for CRT -97% LBBB | 29 | 59% | 6 | LVEF baseline 26% HBP 32% BVP 31% | QRSd Baseline 169 ms NSHBP 160 ms SHBP 171 ms BV 165 ms | Improved NYHA class Improved 6-min walk Improved quality of life |
| Aijola et al. 2017* | Single centre Prospective Observational | HBP for CRT | 21 | 76% | 12 | LVEF 27–41% LVEDD 5.4 to 4.5 cm | QRSd 190 to 129 ms | NYHA III to II |
| Sharma et al. 2019* | Multicentre Prospective Observational | HBP for CRT after BVP failure or primary HBP 45% BBB 39% paced 16% AVB | 106 | 90% | 14 | LVEF 30–44% LVEF 25–40% (LVEF <35%) LVEDD 55 to 54 mm | QRSd 157 to 118 ms | NYHA 2.8 to 1.8 Demonstrates HBP feasibility and safety as an alternative to CRT |
| Upadhyay et al. 2019** | Multicentre Prospective Randomised crossover trial | HBP for CRT in LBBB | 41 | 76% | 12 | LVEF 26–32% | QRSd 172 to 144 ms | Demonstrates feasibility and safety of HBP as an alternative to CRT |
| Huang et al. 2019** | Single centre Prospective Observational | HBP in LBBB, NYHA II–IV with CRT or pacing indication | 74 | 76% | 37 | LVEF 31–57% LVEF 140 to 65 ml | QRSd Baseline 171 ms HBP 113 ms SHBP 173 to 105 ms NSHBP 161 to 140 ms | NYHA 2.8 to 1.0 HBP corrected LBBB in most patients with HF and typical LBBB |
| **His Bundle Pacing in Right Bundle Branch Block** | | | | | | | |
| Sharma et al. 201822 | Multicentre Retrospective Observational | HBP in RBBB QRSd ≥120 ms NYHA class II–IV LVEF ≤50% | 39 | 95% | 15 | LVEF 31–39% LVEF 26 to 34% (LVEF ≤35%) 19% super-responders | QRSd 158 to 127 ms | NYHA 2.8 to 2.0 HBP appears to be a reasonable therapy for patients with RBBB and depressed LVEF |
| **Left Bundle Branch Pacing** | | | | | | | |
| Vijayaraman et al. 2019** | Single centre Prospective Observational | LBBP for bradycardia or CRT (11%) if CS lead or HBP failed LBBB 24% RBBB 25% IVC 8% AV block 6% | 100 | 93% | 3 | n/a | QRSd 133 to 136 ms QRSd 162 to 137 ms for LBBB subgroup | LBBP feasible Low thresholds observed |
| Huang et al. 2020* | Multicentre Prospective Observational | Non-ischaemic cardiomyopathy LBBB LVEF ≤50% | 63 | 97% | 12 | LVEF 33–55% LVEF 123 to 67 ml | QRSd Baseline 169 ms LBBB 118 ms | NYHA 2.8 to 1.4 LBBP may be a reasonable therapy for patients with LBBB and non-ischaemic cardiomyopathy |
| Wu et al. 2020* | Prospective Observations Case control | CRT with BVP, HBP or LBBP in LVEF <40%, LBBB | 137 | 100% | 12 | ΔLVEF 24% | QRSd Baseline 166 ms LBBP 111 ms | Echo outcomes were similar to HBP and significantly greater than BVP |
| Vijayaraman et al. 2021** | Multicentre Retrospective Observational | CRT pacing LVEF <50% | 325 | 85% | 6 | LVEF 33–44% LVEDD 56 to 54 mm LVESV 104 to 83 ml LVEF 27–40% (LVEF ≤35%) Response 73% Super-response 31% | QRSd 152 to 137 ms LBBB Subgroup 162 to 133 ms | NYHA 2.7 to 1.8 LBBB (OR 3.96, p<0.01) LVEDD (OR 0.62, p<0.01) were independent predictors of response LBBP may be a reasonable CRT alternative |
| **His-Optimised Cardiac Resynchronisation Therapy** | | | | | | | |
| Vijayaraman et al. 2019** | Multicentre Retrospective Observational | HOT-CRT in LBBB and IVC with QRS ≥140 ms or AV block with LBBB type escape | 27 | 93% | 12 | LVEF 24–38% LVEDD 65 to 59 mm LVESV 225 to 200 ml LVEF 171 to 138 ml Super-response 28% | QRSd Baseline 183ms BV 162 ms HBP 151 ms HOT-CRT 120 ms | NYHA 3.3 to 2.0 Reduced HF hospitalisations Reduced loop diuretic and aldosterone antagonist doses |
Vijayaraman et al. reported a single centre observational series evaluating the feasibility of LBBP in 100 patients about 24% of whom had LBBB and 11% of total cases had a CRT indication.

In patients with LBBB, the QRSd could be significantly narrowed from 162 ± 21 ms at baseline to 137 ± 19 ms during LBBP (p<0.001). At 3-month follow-up (n=68), the pacing thresholds and sensing remained stable at 0.68 ± 0.21 V at 0.5 ms (p=0.51) and 12.3 ± 5.7 mV (p=0.21), respectively. Only 11% of cases in this study had a CRT indication which limited the evaluation of LBBP for CRT.

Huang et al. reported a 97% success rate with LBBP in a prospective multicentre study involving 137 patients with non-ischaemic cardiomyopathy (49 HBP, 32 LBBP and 54 BVP).

Mean paced QRSd was 100.7 ± 15.3 ms, 110.8 ± 11.1 ms and 135.4 ± 20.2 ms during HBP, LBBP, and BVP, respectively. HBP and LBBP demonstrated a similar absolute increase (Δ) in LVEF (+23.9% versus +24%, p=0.977) and rate of normalised final LVEF (74.4% versus 70.0%, p=0.881) at 1-year follow-up. This was significantly higher than in the BVP group (Δ LVEF +16.7% and 44.9% rate of normalised final LVEF, p< 0.005). HBP and LBBB also demonstrated greater improvements in NYHA class compared with BVP. LBBP was associated with higher R-wave amplitude (11.2 ± 5.1 mV versus 3.8 ± 1.9 mV).

Huang et al. reported a 97% success rate with LBBP in a prospective multicentre study involving 137 patients with non-ischaemic cardiomyopathy (49 HBP, 32 LBBP and 54 BVP). Mean paced QRSd was 100.7 ± 15.3 ms, 110.8 ± 11.1 ms and 135.4 ± 20.2 ms during HBP, LBBP, and BVP, respectively. HBP and LBBP demonstrated a similar absolute increase (Δ) in LVEF (+23.9% versus +24%, p=0.977) and rate of normalised final LVEF (74.4% versus 70.0%, p=0.881) at 1-year follow-up. This was significantly higher than in the BVP group (Δ LVEF +16.7% and 44.9% rate of normalised final LVEF, p< 0.005). HBP and LBBB also demonstrated greater improvements in NYHA class compared with BVP. LBBP was associated with higher R-wave amplitude (11.2 ± 5.1 mV versus 3.8 ± 1.9 mV).

**Table 1: Cont**

| Study          | Design               | Indication                  | n    | Success rate | Follow-up (months) | ECG/QRSd                  | Outcomes                          |
|----------------|----------------------|-----------------------------|------|--------------|---------------------|---------------------------|-----------------------------------|
| Deshmukh 2020 | Retrospective        | HOT-CRT in LBBB and non-LBBB, HBP without BBB correction | 21   | 30           |                     | QRSd: Baseline 171 ms, BVP 141 ms, HBP 157 ms | NYHA 3 to 1, Reduced HF hospitalisations |

**Figure 2: His Bundle Pacing for Cardiac Resynchronisation Therapy in Left Bundle Branch Block**

The patient is a 67-year-old woman with a history of non-ischaemic cardiomyopathy, LVEF 15–20% and NYHA class III. She has a baseline LBBB and QRSd of 152 ms (A), with the distal His location on an right anterior oblique fluoroscopic view (B) and a noted His-ventricular interval of 48 ms (B). A guide wire is placed in a lateral coronary sinus branch through a coronary sinus guide to measure the QLV interval (B). HBP results in selective His capture with LBBB recruitment resulting in narrow paced QRS with a QLV of 70 ms and loss of capture threshold of 1 V at 1 ms (D). Final paced ECG with complete recruitment and selective His bundle pacing with a paced QRSd of 88 ms (E). HBP = His bundle pacing; LBBB = left bundle branch block; LV = left ventricle; LVESD = left ventricular end systolic diameter; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; QRSd = QRS diameter; SBP = systolic blood pressure; SHBP = selective His bundle pacing; ∆ = change in EF. Source: Herweg et al. 2020. © Adapted with permission from Oxford University Press.
mV, p< 0.001) and lower pacing threshold (0.49 ± 0.13 V/0.5 ms versus 1.35 ± 0.73 V/0.5 ms, p<0.001) compared with HBP. Although non-randomised, this study demonstrated that both HBP and LBBP may be superior to BVP when evaluating echocardiographic response.

The largest retrospective multicentre study assessing the feasibility of LBBP for CRT was published by Vijayaraman et al in 2021. LBBB pattern was noted in 39% of this cohort, RBBB in 17% and intraventricular conduction defect in 15%. CRT was successfully achieved by LBBP in 277 of the 325 patients (85%) in which it was attempted and resulted in a significant reduction in QRSd from 152 ± 32 ms to 137 ± 22 ms (p<0.01). LVEF improved from 33 ± 10% to 44 ± 11% (p<0.01) and was noted in both ischaemic and non-ischaemic patients. The lead threshold and R wave amplitude (0.6 ± 0.3 V at 0.5 ms and 10.6 ± 6 mV at implantation) remained stable during follow-up of 6 ± 5 months. Clinical response was noted in 72% and echocardiographic response in 73% of patients while 31% of patients were super-responders.

Patients with Right Bundle Branch Block and HFrEF

It has been demonstrated that BVP-CRT benefits patients with LBBB more than patients with RBBB or RVCD patterns. In patients with typical isolated RBBB, it is the RV that contracts asynchronously with normal LV activation. Hence, BVP-CRT may not correct this delayed RV activation and may not improve outcomes in patients with RBBB. On the other hand, in patients with correction of RBBB with HBP, delayed RV activation can be overcome while maintaining near normal LV activation.

Sharma et al. reported their multicentre findings with HBP in RBBB. HBP was attempted in patients with HFrEF and RBBB, with an overall success rate of 95% (37 of 39 patients) including complete correction of RBBB in 78% of cases. Over a mean follow-up of 15 months, a significant narrowing of QRS from 158 ± 24 ms to 127 ± 17 ms (p=0.0001), with an improvement in LVEF (31 ± 10% to 39 ± 13%) (p=0.004) and NYHA functional class from 2.8 ± 0.6 to 2 ± 0.7 (p=0.0001) was noted with HBP. His capture and BBB correction thresholds were 1.1 ± 0.6 V and 1.4 ± 0.7 V at 1 ms, respectively. An increase in capture threshold occurred in three patients. This was the first multicentre observational analysis signaling that HBP might be an ideal strategy for CRT in patients with RBBB and HFrEF.

Patients with Pacing-Induced Ventricular Dyssynchrony and HFrEF

Conventional RV apical pacing leads to ventricular dyssynchrony which can predispose to PICM in a subset of patients. Recent data suggest that this risk can be as high as one in five patients among patients with an RV pacing burden ≥20%. CSP can help resynchronise ventricular activation thereby resulting in resolution of cardiomyopathy. Most of the studies evaluating this indication have evaluated HBP as an option for CRT. The multicentre findings on HBP for CRT by Sharma et al. included 31 patients with PICM with successful HBP in 81% patients (25 of 31). Shan et al. demonstrated a success rate of 89% among the 18 patients undergoing attempted HBP upgrade, 11 of which were patients with PICM. In this study, the QRSd decreased from 157 ± 22 ms to 107 ± 17 ms, p<0.01. During a 1-year follow-up, left ventricular end-diastolic dimensions decreased from baseline 62 ± 7 mm to 56 ± 8 mm (p<0.01) and LVEF increased from 36 ± 8% to 53 ± 10% (p<0.01).

Shan et al. demonstrated a success rate of 89% among the 18 patients undergoing attempted HBP upgrade, 11 of which were patients with PICM. In this study, the QRSd decreased from 157 ± 22 ms to 107 ± 17 ms, p<0.01. During a 1-year follow-up, left ventricular end-diastolic dimensions decreased from baseline 62 ± 7 mm to 56 ± 8 mm (p<0.01) and LVEF increased from 36 ± 8% to 53 ± 10% (p<0.01).

Vijayaraman et al. published a multicentre observational study with HBP in patients with longstanding AVB and chronic RV pacing and/or PICM in...
need of CRT. HBP was successful in 79 of 85 patients (93%) with chronic RV pacing. QRSd increased from 123 ± 31 ms at baseline to 177 ± 17 ms (p<0.001) during RV pacing and decreased to 115 ± 20 ms with HBP (p<0.001). HBP threshold was 1.47 ± 0.9 V at 1 ms at implant and 1.9 ± 1.3 V at 1 ms over a mean 2-year follow-up. In 60 patients with PICM in whom LVEF decreased from 54 ± 7% at baseline to 34.3 ± 9.6% (p<0.001) with RV pacing, there was an improvement of 48.2 ± 9.8% (p<0.001) after HBP.

Patients Undergoing Atioventricular Node Ablation and HFrEF

Intuitively, CSP may be the best strategy for maintenance of ventricular synchrony in patients with permanent AF, narrow QRSd at baseline and HFrEF undergoing an AVN ablation. In patients with intact distal AV conduction, BVP-CRT creates dyssynchrony by activating endocardial RV and epicardial LV after an AVN ablation. On the other hand, CSP preserves synchronised ventricular activation by pacing the intact native conduction system distal to the site of AVN ablation.

Vijayaraman et al. published their initial findings of HBP among 42 patients undergoing AVN ablation and demonstrated a 95% success rate. HBP threshold at implant was 1 ± 0.8 V at 1 ms and increased to 1.6 ± 1.2 V at 1 ms during a mean follow-up of 19 ± 14 months. Patients with LVEF ≤40% at baseline demonstrated a significant improvement in LVEF (33 ± 7% to 45 ± 9%, p<0.001) while those with an LVEF >40% at baseline, demonstrated a preserved LVEF (56 ± 5% to 57 ± 7%, p=0.5) during follow-up.

Huang et al. similarly evaluated HBP with AVN ablation in 52 patients, half of whom had HFrEF. HBP and AVN ablation was successful in 42 patients (80.8%). Over a median follow-up of 20 months, the LVEF increased significantly from baseline in patients with HFrEF (n=20). NYHA functional status improved 2.9 ± 0.6 to 1.4 ± 0.4 after HBP in patients with a low LVEF. The number of patients who required diuretics for HF decreased significantly (p<0.001).

Wang et al. evaluated 86 consecutive patients with persistent AF and HF who had indications for ICD implantation and split them into patients receiving HBP/LBBP with ICD and AVN ablation (n=52) and the remaining patients underwent ICD implantation only (n=31). During follow-up, patients with HBP/LBBP and AVN ablation had a lower incidence of inappropriate shocks (15.6% versus 0%, p<0.01) and adverse events (p<0.01) and a higher improvement in LVEF and reduction in LV end-systolic volume (15% versus 3%, p<0.001; and 40 ml versus 2 ml, p<0.01, respectively).

The above studies have highlighted that HBP and LBBP are reasonable options for CRT for patients undergoing AVN ablation. However, the observational nature and lack of randomisation to conventional BVP-CRT are limitations of these studies.

Non-responders to Biventricular Cardiac Resynchronisation Therapy

Limited data exists on CSP in patients who have not responded to traditional BVP-CRT. In our multicentre study on HBP for CRT, we had eight patients who were deemed non-responders to BVP-CRT that underwent a successful upgrade to HBP. Six patients (75%) had an echocardiographic response with HBP with an average increase in LVEF from 30 ± 10% to 38 ± 13% (p=0.07).

Similarly, in the study by Shan et al. there were five patients who had successful upgrade to HBP with improvements in LVEF and NYHA functional class. Although these are interesting findings, the small sample size in these studies and the varied definition of non-response to BVP-CRT, this sub-group of patients needs further careful evaluation before CSP can be considered a standard approach.

Patients with Intraventricular Conduction Delay and HFrEF

Most IVCD patterns with QRSd <150 ms typically represent intramyocardial cell-to-cell conduction delay and may not benefit from CSP given the lack of focal disease within the AV conduction system. However, in patients with advanced cardiomyopathy and dilated ventricles, AV conduction disease such as LBBB and intramyocardial delay may coexist. In these circumstances, resynchronisation may be more complete with pacing at the level of both the specialised conduction system (distal to site of AV delay) in conjunction with sequential LV pacing in areas of delayed myocardial activation, referred to as His-optimised CRT (HOT-CRT).

HOT-CRT was evaluated in a small series of patients by Vijayaraman et al. In this study, 27 patients with LBBB/IVCD in whom only partial or no QRS narrowing was achieved by HBP alone, underwent an LV epicardial lead implantation in addition to HBP. HOT-CRT resulted in improved electrical resynchronisation when compared with conventional BVP or HBP alone and was felt to be the best clinical option for these patients. The QRSd reduced from 183 ± 27 ms at baseline to 120 ± 16 ms (34%) with HOT-CRT compared to 162 ± 18 ms (11%) by conventional BVP (p<0.05).

There was an observed significant echocardiographic and clinical improvement in 95% of patients with advanced HF treated with HOT-CRT.

Left Bundle Branch Pacing Versus Left Ventricular Septal Pacing

LBBP and LV septal pacing may be able to overcome more distal conduction disease, such as intrahisian disease, proximal BB disease, and might provide a better opportunity for synchronised LV activation than HBP in such cases. However, LV septal pacing alone versus LBBP (which involves capture and engagement of the left fascicular system) are mechanistically different in LV activation. How this affects resynchronisation, particularly in patients with LBBB and the need for CRT has been evaluated acutely in two studies.

The effects of temporary LV septal pacing without left fascicular system capture were studied in a canine model with LBBB and a human study with LBBB by the Maastricht group. Electrocardiography measuring QRSd, vectorcardiography measuring QRS area, and multielectrode body surface mapping, measuring standard deviation of activation times, were used to assess electrical resynchronisation. LV septal pacing resulted in a larger reduction in QRSd/area and LV activation time when compared to BVP or LV septal and RV pacing. Basal, mid- and apical LV septal pacing positions resulted in similar results, indicating that within the LV septum, the position of the pacing electrode is not critical. Changes in QRS area, LV activation time and LVOpidmax were comparable between LV septal and HBP suggesting that electrical resynchronisation and haemodynamic improvement with LV septal pacing may be as good as that with BVP or HBP in the short term.

Anecdotally, LV septal capture might be reasonable for patients with normal or mildly depressed LVEF, but whether it truly adds value as a strategy for CRT in patients with HFrEF, particularly in those with severely depressed LVEF and a dilated LV cavity remains unknown. The long-term clinical benefit of LV septal pacing compared to HBP or LBBP, particularly in the CRT-indicated patient still needs further systematic evaluation.
During LBBB and LV septal pacing, RBBB delay pattern is often seen in varying degrees due to late activation of the RV. The implications of RV dyssynchrony likely induced by this RBBB pattern in patients undergoing CRT is unclear. However, this RBBB delay/dyssynchrony can be minimised by fusing with native RBB conduction using AV optimisation, bipolar pacing with anodal capture of RV septum, or fusion with RV or RBB pacing using another lead.

**Proposed Algorithm for Conduction System Pacing**

Figure 4 summarises a proposed algorithm for CRT using CSP. As noted above, BVP may not be the ideal resynchronisation strategy for patients with HFREF and RBBB, and HBP likely provides the best option for biventricular activation. In cases with incomplete or no correction of RBBB pattern with HBP, RV pacing can be combined with HBP to pre-excite the RV and provide resynchronisation. BVP still remains the gold standard for CRT for patients with LBBB and HFiEF. CSP with HBP may be considered as a primary or rescue strategy in such cases. If HBP results in correction of LBBB with a correction threshold ≥ 1.5 V at 1 ms, LBBB should be considered. If HBP or LVPP result in partial correction, HOT/LOT-CRT may be performed by combining CSP with LV pacing. Similarly, for patients with an IVCD pattern, combining CSP with LV pacing may be an option. AV delay optimisation with any of these above strategies, particularly with LBBP, can result in further narrowing of the QRS width and help with RV activation.

**Challenges with Conduction System Pacing**

Despite a significant benefit and evolving indications for traditional BVP-CRT, limitations during implant such as the lack of suitable coronary sinus venous branches and unavoidable phrenic nerve stimulation at ideal anatomic LV lead positions can result in failure to achieve optimal CRT. CS lead dislodgement or increasing thresholds (if the lead is placed close to areas of scarring) can be issues in follow-up.

Similarly, both HBP and LBBB may not be successful in achieving CRT in all cases given the level of conduction system disease, presence of IVCD (myocardial conduction delay) and many cases with significant LV remodelling (with mixed conduction disease and myocardial delay).

In recent studies reported above, CSP has been reported to achieve successful CRT in 76-97% of cases. HBP may be associated with an increase in capture thresholds or loss of BBB recruitment thresholds in follow-up. For instance, in the multicentre study on HBP for CRT by Sharma et al., an increase in HB capture threshold (defined as a >2 V increase in capture threshold from implant or capture threshold >5 V at 1 ms) was noted in seven (7.4%) cases, three of which resulted in loss of BBB recruitment. All of these occurred late during follow-up (>6 months postimplant) due to progressive increase in His capture threshold. Repeat procedures were needed in three patients (HBP extraction with manual traction and replacement with LV lead). Whether these increases are related to progression in conduction disease, microdislodgement of the lead (with cardiac motion) or lead-related properties remains unanswered. With LBBP, although thresholds have been reported to be stable during follow-up, long-term issues such as loss of LBB capture, lead dislodgement and the rarely reported complication of late LV septal perforation (into the LV cavity) have been reported.

**Future Directions**

HBP and LBBP may provide a true physiological pacing strategy in patients with an intact distal His-Purkinje system. The above data suggest there is a potential value of this form of pacing for cardiac resynchronisation. CSP offers a promising alternative to BVP in non-responders or as a rescue strategy in those who fail BVP. While preliminary data from small, randomised, crossover studies suggest an equivalent response, it is important to emphasise that there have been no published large-scale randomised trials comparing the effectiveness of HBP or LBBP for CRT in comparison to BVP-CRT.

There are other unanswered questions to be considered:

- What is the degree of correction necessary to achieve electrical and mechanical resynchronisation with HBP or LBBP?
- Are there patient or ECG characteristics that can help predict patients who will achieve successful HBP and will respond to this therapy?
- Is one of these sites for CSP better than the other when looking at clinical outcomes?
Conduction System Pacing for CRT

**Clinical Perspective**

- **Conduction system pacing (CSP) which includes His bundle pacing and the left bundle branch pacing is a promising tool for patients who need ventricular pacing.**
- **CSP can also overcome bundle branch block patterns and thereby alleviate ventricular dyssynchrony.**
- **There are a number of studies demonstrating the clinical benefit of CSP in patients with heart failure, depressed LV function and known ventricular dyssynchrony.**
- **CSP might provide an additional modality for cardiac resynchronization therapy in addition to conventional biventricular pacing.**

**Is LBBB with left fascicular capture better/necessary for resynchronization or is LV septal capture alone enough to improve outcomes in patients with HF-EF and LBBB?**

Larger, multicentre, randomised studies are needed to evaluate the clinical efficacy of these strategies and help answer some of these questions.

**Conclusion**

CSP is a promising technique for ventricular pacing and helps maintain synchronous ventricular contraction. It can correct ventricular dyssynchrony in some patients and more data are emerging on the potential benefit of CSP for CRT. Larger randomised controlled trials and registry data can help realise the true benefit of CSP in comparison to BVP-CRT.

---

1. Deshmukh P, Casavant DA, Romainshyn M, et al. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing. In patients with normal His-Purkinje activation. Circulation 2000;101:869–77. doi.org/10.1161/01.CIR.101.8.869. PMID: 10694526.
2. Sharma PS, Danestamud, G, Naperkowski A, et al. Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm 2015;12:305–12. doi.org/10.1016/j.hrthm.2014.10.021. PMID: 25395066.
3. Abdelrahman M, Subzposh FA, Beer D, et al. Clinical outcomes of His bundle pacing compared to right ventricular pacing. J Am Coll Cardiol 2018;71:295–30. doi.org/10.1016/j.jacc.2018.02.048. PMID: 29355066.
4. Sharma PS, Ellenbogen KA, Trohman RG, Permanent His bundle pacing: the past, the present, and the future. J Cardiovasc Electrophysiol 2017;28:458–65. doi.org/10.1111/jce.13154. PMID: 28023041.
5. Zanor F, Ellenbogen KA, Danestamug D, et al. Permanent His bundle pacing: a literature review and meta-analysis. Europace 2020;22:1819–26. doi.org/10.1093/europace/euz058. PMID: 29708122.
6. Huang W, Su L, Wu, S, et al. Novel pacing strategy with low and stable output: pacing the left bundle branch immediately beyond the conduction block. Can J Cardiol 2017;33:1756–66. doi.org/10.1016/j.cjca.2017.09.003. PMID: 29713511.
7. Cleden JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1593–49. doi.org/10.1056/NEJMoa0502485. PMID: 15753115.
8. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy in advanced chronic heart failure. N Engl J Med 2004;350:2140–50. doi.org/10.1056/NEJMoa0423243. PMID: 15205205.
9. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:845–53. doi.org/10.1056/NEJMoa013168. PMID: 12063368.
10. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioverter defibrillation in advanced chronic heart failure: the MARBLE ICD Trial. JAMA 2008;299:2685–94. doi.org/10.1001/jama.289.20.2685. PMID: 18177115.
11. Cazeau S, Lestréorz C, Lavergne T, et al. Effects of multibundle pacing on patients with heart failure and intravenous conduction delay. J Am Coll Cardiol 2001;38:1344–50. doi.org/10.1016/S0735-1097(01)01895-X. PMID: 12084608.
12. Keshi EI, Leysorgue T, Kumar R, et al. Incidence and predictions of right ventricular pacing-induced cardiomyopathy in patients with complete atioventricular block and preserved left ventricular systolic function. Heart Rhythm 2016;13:2272–80. doi.org/10.1016/j.hrthm.2016.09.027. PMID: 27855853.
13. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:1257–318. doi.org/10.1016/j.jacc.2012.07.009. PMID: 22957230.
14. Sing JP, Klein HH, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial (MADIT-CRT) trial. Circulation 2011;123:1559–66. doi.org/10.1161/CIRCULATIONAHA.110.006466. PMID: 21082895.
15. Moss AJ, Heij WJ, Camm AD, et al. Cardiac resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1599–738. doi.org/10.1056/NEJMoa0905937. PMID: 19640417.
16. Vijayaraman P, Naperkowski A, Subzposh FA, et al. Permanent His-bundle pacing: long-term lead performance and clinical outcomes. J Heart Rhythm 2018;35:656–702. doi.org/10.1016/j.jehrth.2017.12.022. PMID: 20724471.
17. Barba-Pluchino R, Manivel Sanchez A, Fernandez-Gomez JM, et al. Ventricular resynchronization therapy by direct His-bundle pacing: a randomized internal defibrillator. Europace 2015;13:83–9. doi.org/10.1093/europace/eu522. PMID: 22933662.
18. Lustgarten DL, Crespo EM, Arkipova-Jenkins, et al. His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: a crossover design comparison. Heart Rhythm 2015;12:1548–57. doi.org/10.1016/j.hrthm.2015.04.542. PMID: 26152059.
19. Ajilota OA, Upadhyay GA, Macias C, et al. Permanent His bundle pacing for cardiac resynchronization therapy: initial feasibility study in a cohort of left ventricular lead failure. Heart Rhythm 2017;14:1533–1538. doi.org/10.1016/j.hrthm.2017.04.003. PMID: 28400315.
20. Sharma PS, Danestamug D, Herweg B, et al. Permanent His bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: a multicenter experience. Heart Rhythm 2018;15:413–20. doi.org/10.1016/j.hrthm.2017.10.034. PMID: 29209292.
21. Sharma PS, Naperkowski A, Bauch TD, et al. Potential benefits of permanent His bundle pacing combined with atrioventricular nodal ablation in atrial fibrillation patients with heart failure with preserved ejection fraction. J Am Heart Assoc 2018;7:e007647. doi.org/10.1161/JAHA.117.007647. PMID: 21365538.
22. Wang S, Su L, Xu J, et al. Feasibility and efficacy of His bundle pacing or left bundle pacing combined with atrioventricular node ablation in patients with persistent atrial fibrillation and implantable cardioverter-defibrillator therapy. J Am Heart Assoc 2019;8:e01253. doi.org/10.1161/JAHA.119.012453. PMID: 31830874.
23. Radmakers LM, van Ham HK, Kuiper M, et al. Possible role for pacing the left ventricular septum in upgrading cardiac resynchronization therapy. JACC Clin Electrophysiol 2021;5:421–22. doi.org/10.1016/j.jcledp.2020.09.010. PMID: 32958589.
24. Seddon F, Luenmers J, Westra SW, et al. Short-term hemodynamic and electrophysiological effects of cardiac resynchronization by left ventricular septal pacing. J Am Coll Cardiol 2020;75:347–59. doi.org/10.1016/j.jacc.2019.11.010. PMID: 32000945.
25. Ravi V, Hanifin JL, Larsen T, et al. Pros and cons of left bundle branch pacing: a single-center experience. Circ Arrhythm Electrophysiol 2020;13:2135–43. doi.org/10.1161/CIRC Arrhythm Electrophysiol.120.008874. PMID: 33198496.
26. Herweg B, Welter-Frost A, Vijayaraman P. The evolution of cardiac resynchronization therapy and an introduction to conduction system pacing: a conceptual review. Europace 2020;22:e288–e298. doi.org/10.1177/1009128620946175. PMID: 32247903.